Search results for "Lung disease"

showing 10 items of 240 documents

Ultrastructural study on human lung in alveolitis versus pulmonary fibrosis

1993

Lung specimens of 21 patients with diffuse interstitial lung disease were examined. The present ultrastructural study outlines the topography and distribution of inflammatory changes in the interstitium, endothelium, and in pneumocytes and phagocytes. Alveolitis is characterized by marked regenerative activity of type II pneumocytes (cuboid metaplasia), intraluminal macrophage accumulation, endothelial swelling, multilamination of the endothelial basement membrane, pericapillary edema, and primarily by cellular infiltrates in the interstitial space. The most prominent feature of the interstitium in pulmonary fibrosis is the lack of immunoinflammatory cells. In some areas there is a marked a…

AdultMalePathologymedicine.medical_specialtyEndotheliumPulmonary FibrosisEpitheliumInterstitial spaceEdemaMacrophages AlveolarDrug DiscoveryPulmonary fibrosismedicineHumansLymphocytesLungGenetics (clinical)InflammationBasement membraneMetaplasiaLungbusiness.industryPneumonia PneumocystisType-II PneumocytesInterstitial lung diseaseGeneral MedicineMiddle Agedrespiratory systemmedicine.diseaseCapillariesmedicine.anatomical_structureImmunologyMolecular MedicineFemalemedicine.symptombusinessAlveolitis Extrinsic AllergicThe Clinical Investigator
researchProduct

Oxygen Radical Production by Alveolar Inflammatory Cells in Idiopathic Pulmonary Fibrosis

1990

Idiopathic pulmonary fibrosis (IPF) is a chronic inflammatory interstitial lung disease characterized by the accumulation of alveolar macrophages (AMs) and neutrophils in the lower respiratory tract, parenchymal cell injury, and fibrosis of the alveolar structure. Reactive oxygen intermediates (ROI) are claimed to be a major cause of tissue damage in IPF; however, the source of ROI has not been unequivocally identified. AMs, as well as neutrophils, are capable of releasing these agents. The contributions of these possible sources are not known. To address this question, we evaluated the spontaneous and stimulated (PMA or zymosan) ROI release of total bronchoalveolar cells and isolated AMs i…

AdultMalePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyFree RadicalsNeutrophilsPrednisolonePulmonary FibrosisCell CountInflammationchemistry.chemical_compoundIdiopathic pulmonary fibrosisFibrosismedicineHumansLungmedicine.diagnostic_testSuperoxide Dismutasebusiness.industryMacrophagesZymosanZymosanInterstitial lung diseaseMiddle Agedrespiratory systemmedicine.diseaserespiratory tract diseasesOxygenPulmonary Alveolimedicine.anatomical_structureBronchoalveolar lavagechemistryLuminescent MeasurementsImmunologyTetradecanoylphorbol AcetateFemalemedicine.symptombusinessBronchoalveolar Lavage FluidRespiratory tractAmerican Review of Respiratory Disease
researchProduct

Determinants of physical activity in daily life in candidates for lung transplantation

2012

BACKGROUND: Participation in daily physical activity (PA) has never been objectively assessed in candidates for lung transplantation (LTx). The main research questions were: 1) How active are LTx-candidates in daily life? 2) What are determinants of activity behavior before LTX? METHODS: Ninety-six candidates for LTx (diagnosis of COPD or interstitial lung disease; mean age 55 ± 7 years) underwent measurements of PA, pulmonary function, 6-min walking distance (6MWD), muscle force and health-status (SF-36 scale). RESULTS: Patients were markedly inactive (5% of waking hours walking, 26% standing and 69% sedentary). Backward multiple regression identified 6MWD (expressed as % of predicted valu…

AdultMaleQuality of lifePulmonary and Respiratory Medicinemedicine.medical_specialtyActivities of daily livingCross-sectional studymedicine.medical_treatmentPhysical activityMEDLINEWalkingMotor ActivityPulmonary Disease Chronic ObstructiveQuality of life (healthcare)Forced Expiratory VolumeActivities of Daily LivingmedicineExercise capacityHumansLung transplantationbusiness.industryPhysical activityMuscle strengthMiddle Agedrespiratory systemExercise capacitymedicine.diseaseRespiratory MusclesCross-Sectional StudiesLung transplantationMood disordersPreoperative PeriodRespiratory MechanicsPhysical therapyMood disordersFemaleSeasonsHuman medicineLung Diseases InterstitialbusinessRespiratory Medicine
researchProduct

Guideline-based survey of outpatient COPD management by pulmonary specialists in Germany

2012

Thomas Glaab1,2, Claus Vogelmeier3, Andreas Hellmann4, Roland Buhl11Department of Respiratory Diseases III, Medical Center of the Johannes Gutenberg-University, Mainz, 2Medical Affairs Germany, Respiratory Medicine, Boehringer Ingelheim Pharma GmbH and Co, KG, Ingelheim, 3Department of Respiratory Diseases, University Hospitals of Giessen and Marburg, Marburg, 4Federal Association of Pneumologists, Augsburg, GermanyBackground: Little is known about the role of guidelines for the practical management of chronic obstructive pulmonary disease (COPD) by office-based pulmonary specialists. The aim of this study was to assess their outpatient management in relation to current guideline recommenda…

AdultMaleSpirometryHealth Knowledge Attitudes Practicemedicine.medical_specialtyChronic bronchitisAttitude of Health Personneldiagnosismedicine.medical_treatmentInternational Journal of Chronic Obstructive Pulmonary DiseasePulmonary Disease Chronic ObstructivePatient Education as TopicAmbulatory careRisk FactorsGermanySurveys and QuestionnairesHealth careAmbulatory CaremedicineHumanssurveyPulmonary rehabilitationGOLDPractice Patterns Physicians'Referral and ConsultationOriginal ResearchtherapyCOPDEvidence-Based Medicinemedicine.diagnostic_testbusiness.industryGeneral MedicineGuidelineMiddle Agedmedicine.diseasepulmonary rehabilitationclinical outcomesObstructive lung diseaseRespiratory Function TestsBenchmarkingCross-Sectional StudiesHealth Care SurveysFamily medicinePractice Guidelines as TopicFemaleGuideline AdherencebusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease

1988

In a six-month multicenter feasibility and safety study, 20 patients, who all had a congenital deficiency of alpha-1-protease inhibitor (A1PI) of the PiZ phenotype accompanied by a chronic obstructive lung disease, were treated with human-plasma-derived A1PI. A weekly dose of 60 mg/kg, administered intravenously, was shown to be sufficient to maintain patient serum levels above the threshold limit of 35 percent, the serum level of healthy persons of the MZ phenotype. This is supposed to be the minimal effective level for protection against the elastolytic attack of the lung and, therefore, satisfies one of the most important criteria of feasibility of long-term replacement therapy. The glob…

AdultMalealpha 1-Antitrypsin DeficiencymedicineHumansLung Diseases ObstructiveInfusions IntravenousAgedRadial immunodiffusionClinical Trials as TopicLungPancreatic Elastasebiologybusiness.industryBlood ProteinsGeneral MedicineMiddle AgedOuchterlony double immunodiffusionTrypsinmedicine.diseaseAlpha-1 Protease Inhibitor DeficiencyObstructive lung diseasePhenotypemedicine.anatomical_structureImmunologybiology.proteinFemaleAntibodyLung Volume MeasurementsbusinessNephelometrymedicine.drugThe American Journal of Medicine
researchProduct

Serum surfactant protein D and exhaled nitric oxide as biomarkers of early lung damage in systemic sclerosis

2017

Background Interstitial lung disease (ILD) complicates the course of systemic sclerosis (SSc), representing the main cause of death in these patients. The identification of parameters that can predict the early onset and progression of ILD in SSc represents an unmet need in clinical practice. The study was designed to explore whether the surfactant proteins (SP) A and D may be used as noninvasive tools for the early identification of ILD in SSc. Alveolar exhaled nitric oxide (NO) was investigated as a surrogate marker of distal inflammation. Methods Unselected consecutive subjects newly diagnosed with scleroderma and subjects free of respiratory and systemic diseases were recruited. All pat…

AdultMalemedicine.medical_specialtyBreath TestSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologySclerodermaScleroderma03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineDLCOInternal medicineMedicineHumansRespiratory systemLungScleroderma Systemicbusiness.industryPulmonary surfactant-associated proteinMedicine (all)SystemicInterstitial lung diseaseSurfactant protein DNitric oxideGeneral MedicineBiomarkerrespiratory systemmedicine.diseasePulmonary Surfactant-Associated Protein Dmedicine.anatomical_structure030228 respiratory systemBreath Tests030220 oncology & carcinogenesisLung diseaseExhaled nitric oxideFemalebusinessInterstitialLung Diseases InterstitialBiomarkersHuman
researchProduct

Investigation into isoprenaline resistance in patients with obstructive lung disease

1974

12 patients with chronic obstructive lung disease have been studied in an investigation regarding the causes of resistance to isoprenaline. The effects of repeated intravenous doses of 10 µg isoprenaline were assessed by cross over comparison before and after infusions of isoprenaline and a placebo; the infusions lasted for 35 to 40 min and the amount of isoprenaline infused was 0.5 µg/min. Total resistance, thoracic gas volume (whole-body plethysmography) and heart rate (ECG) were measured. No decrease in bronchospasmolytic or positive chronotopic effects on single isoprenaline injections could be demonstrated after prolonged infusions of isoprenaline.

AdultMalemedicine.medical_specialtyDrug ResistanceDrug resistancePlaceboPlacebosElectrocardiographyHeart RateIsoprenalineInternal medicineHeart ratemedicineHumansPlethysmographInfusions ParenteralPharmacology (medical)Lung Diseases ObstructiveAgedPlethysmography Whole BodyAsthmaPharmacologyAnalysis of VarianceClinical Trials as Topicbusiness.industryAirway ResistanceIsoproterenolGeneral MedicineMiddle Agedmedicine.diseaseStimulation ChemicalObstructive lung diseaseAirway ObstructionBronchodilatationAnesthesiaInjections IntravenousCardiologyFemalebusinessmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Automatic detection and quantification of ground-glass opacities on high-resolution CT using multiple neural networks: comparison with a density mask.

2000

We compared multiple neural networks with a density mask for the automatic detection and quantification of ground-glass opacities on high-resolution CT under clinical conditions.Eighty-four patients (54 men and 30 women; age range, 18-82 years; mean age, 49 years) with a total of 99 consecutive high-resolution CT scans were enrolled in the study. The neural network was designed to detect ground-glass opacities with high sensitivity and to omit air-tissue interfaces to increase specificity. The results of the neural network were compared with those of a density mask (thresholds, -750/-300 H), with a radiologist serving as the gold standard.The neural network classified 6% of the total lung a…

AdultMalemedicine.medical_specialtyOpacityAdolescentPulmonary FibrosisHigh resolutionSensitivity and SpecificityRadiographic image interpretationAbsorptiometry PhotonPredictive Value of TestsmedicineImage Processing Computer-AssistedHumansRadiology Nuclear Medicine and imagingProspective StudiesLungAgedAged 80 and overArtificial neural networkbusiness.industryFollow up studiesMean ageGeneral MedicinePneumoniaMiddle AgedSurgeryLung diseaseRadiographic Image Interpretation Computer-AssistedFemaleTomographyNeural Networks ComputerNuclear medicinebusinessTomography X-Ray ComputedFollow-Up StudiesAJR. American journal of roentgenology
researchProduct

The Potential Role of Lung Ultrasound B-Lines for Detection of Lung Radio-Induced Toxicity in Breast Cancer Patients after Radiation Therapy.

2016

Breast cancer patients exposed to doses of radiation after radiotherapy could develop toxicity to lung. Lung ultrasound (LUS) is able to detect interstitial lung disease by the evaluation of B-lines. The aim of our study was to assess the number of B-lines to diagnose lung involvement after chest radiotherapy.We measured LUS B-lines in the treated and contralateral lung of 20 breast cancer patients, 1-3 months after the end of radiotherapy and 1 year after previous LUS. The sum of the B-lines number in the 72 sites on anterior and posterior chest yielded a global B-lines score.B-lines were more numerous in treated (median: 21; 1st-3rd quartiles: 11-31) versus untreated hemithorax (median: 3…

Adultmedicine.medical_specialtymedicine.medical_treatmentBreast Neoplasms030204 cardiovascular system & hematologySensitivity and Specificity03 medical and health sciences0302 clinical medicineBreast cancermedicineHumansRadiology Nuclear Medicine and imagingStage (cooking)Subclinical infectionUltrasonographyLungbusiness.industryInterstitial lung diseaseReproducibility of ResultsMiddle Agedmedicine.diseaseRadiation therapyRadiation Pneumonitismedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisToxicityBiomarker (medicine)Feasibility StudiesFemaleRadiotherapy AdjuvantRadiologyRadiotherapy ConformalCardiology and Cardiovascular MedicinebusinessEchocardiography (Mount Kisco, N.Y.)
researchProduct

Difference in Mortality Risk in Elderly People with Bronchial Obstruction Diagnosed Using a Fixed Cutoff or the Lower Limit of Normal of the FEV1/FVC…

2017

Background: Whether a fixed cutoff or the lower limit of normal of the FEV1/FVC ratio should be used to diagnose bronchial obstruction is still a matter of debate. This issue is particularly important for elderly people. Objectives: We used equations applicable up to 90 years of age to evaluate the mortality of elderly people diagnosed with bronchial obstruction using either a fixed cutoff of 0.7 or the lower limit of normal (LLN). Methods: Participants in the SaRA (Salute Respiratoria nell'Anziano, Italian for "Respiratory Health in the Elderly") study were grouped as follows: FEV1/FVC ≥0.7 and ≥ LLN (n = 535: F-/L-), FEV1/FVC <0.7 but ≥ LLN (n = 118: F+/L-), and FEV1/FVC <0.7 and < LLN (n…

Aged 80 and overMalePulmonary and Respiratory MedicineVital CapacityBronchial obstructionSettore MED/10 - Malattie Dell'Apparato RespiratorioRisk AssessmentLower limit of normalAlgorithmFixed cutoffElderlyItalyForced Expiratory VolumeHumansFemaleLung Diseases ObstructiveAlgorithmsAgedHuman
researchProduct